BioNTech, Neon Take A Step Forward In Personalized Cancer Vaccines

Two studies published in Nature July 5 showed that personalized cancer vaccines from BioNTech and Neon Therapeutics delivered potent immune responses in patients with melanoma. Both companies are moving forward with new studies.

Two early studies published in Nature July 5 showed promise for individualized cancer vaccines based on patient-specific tumor mutations, further reviving optimism for therapeutic cancer vaccines, a field of research that has generated excitement and disappointment over the years.

One of the approaches profiled in Nature involved BioNTech AG's individualized RNA vaccine IVAC Mutanome, developed in collaboration with the translational research institute, TRON. The other was a neoantigen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.